Ebastine in perennial allergic rhinitis.

Abstract

Oral ebastine, 10 mg once daily for seven days, and placebo were compared as treatment for active perennial allergic rhinitis in 151 patients in a multicenter, randomized, double-blind trial. Ebastine treatment produced a significant reduction in the incidence and severity of most symptoms associated with perennial rhinitis. Tolerability was similar in the two treatment groups. The incidences of drowsiness and dry mouth were not more frequent in the patients treated with the active drug.

• Authors: C Picado Vallés, A Cadahia García, A Cisteró Bahima, L Cano Cantudo, A Sanz Amaro, J M Zayas Sanza
• Journal: Annals of allergy (Ann Allergy) Vol. 67 Issue 6 Pg. 615-8 (Dec 1991) ISSN: 0003-4738 [Print] United States
• PMID: 1684273 (Publication Type: Clinical Trial, Journal Article, Multicenter Study, Randomized Controlled Trial)

Chemical References

• Butyrophenones
• Histamine H1 Antagonists
• Piperidines
• ebastine

Topics

• Adult
• Butyrophenones (adverse effects, standards, therapeutic use)
• Double-Blind Method
• Female
• Histamine H1 Antagonists (adverse effects, standards, therapeutic use)
• Humans
• Male
• Piperidines (adverse effects, standards, therapeutic use)
• Rhinitis, Allergic, Perennial (drug therapy)
• Time Factors